[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

623.O2.6 Lymphoma: Chemotherapy, excluding Pre-Clinical Models - Non-Hodgkin Lymphoma: Therapy

Oral and Poster Abstracts
Oral Session
Monday, December 7, 2009: 10:30 AM-12:00 PM
208-210 (Ernest N. Morial Convention Center)
Fritz Offner, MD and Philip J. Bierman
10:30 AM
R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin’s Lymphoma Outcomes Database Project

Ann LaCasce, MD1, Jonathan L. Vandergrift, MS2*, Maria A. Rodriguez, MD3*, Allison L. Crosby, MS1*, Eva M. Lepisto, MSc, MA2*, Myron S. Czuczman, MD4, Auayporn P. Nademanee, MD5, Douglas W. Blayney, MD6, Leo I. Gordon, MD7, Michael Millenson, MD8, Ann Vanderplas5*, Gregory A. Abel, MD, MPH1, Andrew D. Zelenetz, MD, PhD9* and Jonathan W. Friedberg, MD10

1Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2National Comprehensive Cancer Network, Fort Washington, PA
3Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston, TX
4Medical Oncology and Immunology, Roswell Park Cancer Institute, Buffalo, NY
5City of Hope National Medical Center, Duarte, CA
6University of Michigan Cancer Center, Ann Arbor, MI
7Department of Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL
8Fox Chase Cancer Center, Philadelphia, PA
9Memorial Sloan-Kettering Cancer Center, New York, NY
10James P. Wilmot Cancer Center, University of Rochester, Rochester, NY

10:45 AM
Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High – Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

Norbert Schmitz1, Maike Nickelsen1*, Marita Ziepert2*, Matthias Haenel3*, Peter Borchmann, PD, Dr.4*, Andreas Viardot5*, Christina Nickenig6*, Martin Bentz, MD7, Christian Peschel, MD8, Lorenz Trümper9*, Markus Loeffler, Prof.2*, Michael Pfreundschuh10 and Bertram Glass, MD, PhD1*

1Hematology and Stem Cell Transplantation, ASKLEPIOS Klinik St. Georg, Hamburg, Germany
2Institute of Medical Informatics, Statistics and Epidemiology, Leipzig, Germany
3Departement of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany
4First Department of Internal Medicine, University of Cologne, Cologne, Germany
5Internal Medicine III, Hematology, University Hospital Ulm, Ulm, Germany
6Medical Clinic III, University Hospital Munich Großhadern LMU, Munich, Germany
7II Medizinischen Klinik, Stadtisches Klinikum Karlsruhe, Karlsruhe, Germany
83rd Medical Department, Hematology and Oncology, Technische Universität München, München, Germany
9Hematology and Oncology, University of Göttingen, Göttingen, Germany
10University of Saarland, Homburg, Germany

11:00 AM
Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany)Clinically Relevant Abstract

Mathias J Rummel, MD, PhD1*, Norbert Niederle2*, Georg Maschmeyer3, Andre Banat, MD, MBA4*, Ulrich von Gruenhagen, MD5*, Christoph Losem6*, Gerhard Heil7*, Manfred Welslau8*, Christina Balser9*, Ulrich Kaiser10*, Harald Ballo11*, Eckhart Weidmann12*, Heinz A Duerk13*, Dorothea Kofahl-Krause14*, Fritz Roller15*, Juergen Barth16*, Dieter Hoelzer, MD, PhD17, Axel Hinke18* and Wolfram Brugger19

1Hematology, University Hospital, Giessen, Germany
2Klinik Leverkusen
3Dept. of Hematology/ Oncology, Ernst-von-Bergmann Clinic, Potsdam, Germany
4Kerckhoff Clinic, University of Giessen, Giessen
5Praxis für Haematologie/Onkologie, Cottbus, Germany
6Praxis for Hematology and Oncology, Neuss, Germany
7Krankenhaus Luedenscheid
8Praxis Aschaffenburg
9Praxis, Marburg, Germany
11Praxis Offenbach
12Krankenhaus Nordwest
14MHH Hannover
15Dept. of Hematology, University Hospital, Gießen, Germany
16University Hospital, Giessen, Germany
17Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital, Frankfurt/M, Germany
18WISP, Langenfeld, Germany
19Dept. of Hematology, Hospital Villingen-Schwenningen, Villingen - Schwenningen, Germany

11:15 AM
R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA StudyClinically Relevant Abstract

Richard Delarue, MD1*, Herve Tilly, MD2, Gilles Salles, MD, PhD3, Christian Gisselbrecht, MD4, Nicolas Mounier, MD5*, Marion Fournier6*, Thierry Jo Molina, MD7*, Caroline Bonmati, MD8*, Hervé Ghesquieres, MD9*, Michel Blanc, MD10*, Delphine Germain6*, Laurence Girard6*, Corinne Haioun, MD11 and Andre Bosly, MD, PhD12

1Hopital Necker, Paris, France
2Centre Henri Becquerel, Rouen, France
3Hematologie, Centre Hospitalier Lyon-Sud, Pierre-Benite, France
4Dept. of Hematology, St. Louis Hospital, Paris, France
5CHU Nice, Nice, France
6Gelarc, Lyon, France
7Pathology, Université Paris Descarte and Hôtel Dieu Hospital, Paris, France
8CHU Nancy, Nancy, France
9Hematology, centre Léon Bérard, Lyon, France
10Centre Hospitalier, Chambery, France
11Service d'Hématologie Clinique, Hôpital Henri Mondor, Créteil, France
12Mont-Godinne Univ., Yvoir, Belgium

11:30 AM
Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II  Study by the NCIC Clinical Trials Group

Laurie H. Sehn, MD, MPH1, David A Macdonald, MD2, Sheldon H. Rubin, MD3, Guy Cantin, MD4*, Morel Rubinger, MD5, Bernard Lemieux, MD6, Sanraj Basi, MD7*, Kevin R Imrie, MD8, Randy D. Gascoyne9, Bingshu Chen, PhD10*, Marina Djurfeldt, MSc10*, Lois Shepherd, MD10*, Stephen Couban, MD11 and Michael Crump, MD12

1Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
2QEII Health Sciences Centre, Halifax, NS, Canada
3The Moncton Hospital, Moncton, NB, Canada
4CHA Hopital Enfant- Jesus, Quebec City, QC, Canada
5Cancercare Manitoba, Winnipeg, MB, Canada
6Hematology and Blood Bank, CHUM-Notre-Dame, Montreal, QC, Canada
7Cross Cancer Centre, Edmonton, AB, Cayman Islands
8Hematology/Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
9Department of Pathology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
10National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada
11Sciences Centre, Queen Elizabeth II Health, Halifax, NS, Canada
12Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada

11:45 AM
R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines

Alden A. Moccia1*, Kimberly Schaff2*, Paul Hoskins1*, Richard Klasa1, Kerry J. Savage1, Tamara Shenkier1*, Randy D. Gascoyne3, Joseph M. Connors1 and Laurie H. Sehn1

1Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
2Department of Pharmacy, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
3Department of Pathology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada

*signifies non-member of ASH